Neil Herskowitz
CIK 1298246 · last filed 2026-07-02
Neil Herskowitz is a corporate insider who has filed 62 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for DERM, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$375.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $4.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.83M
9
62
$375.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DERM | Director | 168,618 | $6.31 | $1.06M | $0 | 8 | 2026-07-02 |
| MBIO | Director | 145 | $0.63 | $92 | $3.7K | 7 | 2025-12-30 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 0 | $4.26 | $0 | $0 | 9 | 2025-05-30 |
| AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Director | 97 | $0.35 | $34 | $321.8K | 20 | 2024-12-03 |
| NATIONAL HOLDINGS CORP (NHLDW) Delisted | Director | 60,593 | — | — | $0 | 1 | 2019-03-06 |
| Origo Acquisition Corp (CNLM.W) Delisted | Director | 0 | — | — | $0 | 1 | 2016-05-23 |
| TGTX | Director | 68,550 | $54.87 | $3.76M | $0 | 1 | 2013-06-07 |
| Chelsea Therapeutics International, Ltd. (CHTP) Delisted | Director | 59,522 | — | — | $0 | 2 | 2008-01-28 |
| TG THERAPEUTICS, INC. (MHA) Delisted | Director | 93,626 | — | — | $50.0K | 2 | 2007-04-09 |
Recent Filings
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | DERM | Grant (A) | +50,000 | $0 | EDGAR |
| 2026-06-26 | DERM | Grant (A) | +10,000 | $0 | EDGAR |
| 2025-12-30 | MBIO | Sell (S) | −247 | -$238 | EDGAR |
| 2025-08-07 | DERM | Grant (A) | +20,000 | $0 | EDGAR |
| 2025-07-07 | DERM | Grant (A) | +7,173 | $0 | EDGAR |
| 2025-05-30 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Mixed | −134,812 | $0 | EDGAR |
| 2024-12-17 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +17,638 | $0 | EDGAR |
| 2024-12-03 | AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Sell (S) | −23 | -$46 | EDGAR |
| 2024-09-25 | AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-07-10 | DERM | Grant (A) | +9,728 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.